AR
ARUXF.US Acrux Limited
- Market cap
- USD 3.67M
- P/E
- -
- P/B
- 3.65x
- ROE
- -41.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is ARUXF.US undervalued?
Graham numberThe Graham number of Acrux Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Acrux Limited fundamental analysis
No fundamental analysis for Acrux Limited yet.
Acrux Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Acrux Limited
Acrux Limited, together with its subsidiaries, develops and commercializes topically applied pharmaceutical products in Australia, the United States, Europe, and internationally. The company offers Dapsone 7.5% and 5% gels for the treatment of acne vulgaris; Nitroglycerine 0.4% ointments for the treatment of moderate to severe pain associated with chronic anal fissure; Lidocaine and Prilocaine creams USP 2.5% for local analgesia and pre-treatment for infiltration anesthesia;…
Full company profileAcrux Limited financial statements
Acrux Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 23.3M | 2.69M | 631K | 1.25M | 1.34M | 1.72M | 8.43M | 5.09M | 1.19M | 4.64M |
| Gross Profit | 23.2M | -2.70M | -4.49M | -3.76M | -7.59M | -4.65M | 7.87M | 1.13M | 1.19M | 4.20M |
| Operating Income | 21.2M | -5.33M | -13.0M | -12.1M | -23.6M | -17.7M | -5.91M | -8.58M | -8.97M | -2.14M |
| EBITDA | 22.8M | -9.33M | -12.6M | -11.4M | -15.6M | -12.3M | -2.81M | -8.08M | -5.17M | -1.70M |
| Net Income | -243K | -14.2M | -8.33M | -9.47M | -12.6M | -9.83M | -764K | -5.80M | -5.95M | -603K |
| EPS | 0.00 | -0.09 | -0.05 | -0.06 | -0.06 | -0.03 | 0.00 | -0.02 | -0.02 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 47.3M | 32.5M | 24.4M | 17.8M | 23.3M | 14.3M | 13.3M | 8.96M | 7.23M | 6.81M |
| Total Liabilities | 3.38M | 2.52M | 2.50M | 4.99M | 4.86M | 5.21M | 4.59M | 5.69M | 6.20M | 5.35M |
| Shareholders' Equity | 43.9M | 30.0M | 21.9M | 12.8M | 18.5M | 9.09M | 8.70M | 3.28M | 1.02M | 1.46M |
| Cash & Short-term Investments | 34.0M | 28.5M | 18.2M | 9.21M | 15.3M | 5.83M | 6.23M | 2.95M | 863K | 1.70M |
| Total Debt | - | - | - | 2.40M | 2.23M | 2.08M | 2.35M | 3.70M | 3.64M | 2.51M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 5.38M | -5.28M | -9.94M | -8.53M | -11.4M | -8.82M | 703K | -4.30M | -5.47M | 1.02M |
| Capital Expenditure | 629K | 296K | 380K | 258K | 102K | 465K | 119K | 276K | 5.00K | 0.00 |
| Free Cash Flow | 4.75M | -5.58M | -10.3M | -8.79M | -11.5M | -9.28M | 584K | -4.58M | -5.48M | 1.02M |
| Ratios | ||||||||||
| ROE | -0.6% | -47.3% | -38.0% | -73.7% | -68.4% | -108.2% | -8.8% | -177.0% | -581.1% | -41.2% |
| ROA | -0.5% | -43.7% | -34.1% | -53.1% | -54.1% | -68.8% | -5.8% | -64.7% | -82.3% | -8.9% |
| Net Profit Margin | -1.0% | -527.8% | -1,319.3% | -755.9% | -944.6% | -572.1% | -9.1% | -113.9% | -499.6% | -13.0% |
| Debt to Equity | - | - | - | 0.19x | 0.12x | 0.23x | 0.27x | 1.13x | 3.55x | 1.72x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Acrux Limited dividends
Acrux Limited has not paid dividends in the last 10 fiscal years.
Who owns Acrux Limited
- Insiders 23.14%
- Institutions 7.02%
- Public & others 69.84%
- Shares outstanding 612M
- Free float 390M
Acrux Limited company profile
- Company name
- Acrux Limited
- Ticker
- ARUXF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 103-113, Stanley Street, West Melbourne, VIC, Australia, 3003
- Phone
- 61 3 8379 0100
- Website
- acrux.com.au
About Acrux Limited
Acrux Limited, together with its subsidiaries, develops and commercializes topically applied pharmaceutical products in Australia, the United States, Europe, and internationally. The company offers Dapsone 7.5% and 5% gels for the treatment of acne vulgaris; Nitroglycerine 0.4% ointments for the treatment of moderate to severe pain associated with chronic anal fissure; Lidocaine and Prilocaine creams USP 2.5% for local analgesia and pre-treatment for infiltration anesthesia; and estradiol transdermal sprays for women for the treatment of moderate to severe hot flushes associated with menopause under the Lenzetto and Evamist brand names. It also provides laboratory and product development services, including in vitro release testing; formulation development; stability and quality check; analytical; generic and pharma development; regulatory; project management and technology transfer; consulting; and co-development services. The company was incorporated in 1998 and is based in West Melbourne, Australia.
Acrux Limited management
5- Mr. John WarmbrunnMD, CEO & Director
- Ms. Joanna Johnson B.E., BEc, ICAACFO & Company Secretary
- Ms. Felicia Colagrande B.Sc., BSc (Hons), M.B.A.Product Development & Technical Affairs Director
- Mr. Mark HymanProject & Technical Development Director
- Dr. Jolanta Airey M.D.Chief Medical Officer